Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
scAAV9.CB.CLN6 in CLN6 Batten Disease
NCT07582484Phase 2Not yet recruiting
- Sponsor
- Charlotte and Gwenyth Gray Foundation
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of sesiclenegene cosaparvovec in neuronal ceroid lipofuscinosis (NCL), sponsored by Charlotte and Gwenyth Gray Foundation. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sesiclenegene cosaparvovec
03
Conditions
neuronal ceroid lipofuscinosis (NCL)
Beyond the preview
Go deeper on NCT07582484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582484.